Sex differences in glycemic measures, complications, discharge disposition, and postdischarge emergency room visits and readmission among non-critically ill, hospitalized patients with diabetes

Neeti Patel,1 Janya Swami,1 Diana Pinkhasova,1 Esra Karslioglu French,1 Deborah Hlasnik,1 Kristin Delisi,1 Amy Donihi,2 Linda Siminerio,3 Daniel J Rubin,4 Li Wang,5 Mary T Korytkowski

ABSTRACT
Introduction The purpose of this prospective observational cohort study was to examine sex differences in glycemic measures, diabetes-related complications, and rates of postdischarge emergency room (ER) visits and hospital readmissions in non-critically ill, hospitalized patients with diabetes.

Research design and methods Demographic data including age, body mass index, race, blood pressure, reason for admission, diabetes medications at admission and discharge, diabetes-related complications, laboratory data (hematocrit, creatinine, hemoglobin A1c, point-of-care blood glucose measures), length of stay (LOS), and discharge disposition were collected. Patients were followed for 90 days after hospital discharge to obtain information regarding ER visits and readmissions.

Results 120 men and 100 women consented to participate in this study. There were no sex differences in patient demographics, diabetes duration or complications, or LOS. No differences were observed in the percentage of men and women with an ER visit or hospital readmission within 30 (39% vs 33%, p=0.40) or 90 (60% vs 49%, p=0.12) days of hospital discharge. More men than women experienced hypoglycemia prior to discharge (18% vs 8%, p=0.026). More women were discharged to skilled nursing facilities (p=0.007).

Conclusions This study demonstrates that men and women hospitalized with an underlying diagnosis of diabetes have similar prediabetes glycemic measures, diabetes duration, and prevalence of diabetes complications. More men experienced hypoglycemia prior to discharge. Women were less likely to be discharged to home. Approximately 50% of men and women had ER visits or readmissions within 90 days of hospital discharge.

Trial registration number NCT03279627.

INTRODUCTION
According to the Center for Disease Control, 17.9 million men and 16.2 million women in the USA had a diagnosis of diabetes in 2018.1 Higher per capita healthcare expenditures are reported in men with diabetes, but higher lifetime healthcare expenditures are reported in women.2–4 These higher costs in women may be due in part to social factors such as lower levels of education, employment, and socioeconomic status, which hinder access to healthcare and healthy lifestyles.5–6 These factors in turn have the potential to increase the risk of diabetes-related complications and associated comorbidities such as cardiovascular disease (CVD), which...
may lead to hospitalization, a major contributor to healthcare costs in people with diabetes.5

Both men and women with diabetes have a higher lifetime likelihood of being hospitalized.7–8 Diabetes is identified as an underlying comorbidity in approximately 25% of all adult hospitalized patients and is also identified as a predictor of risk of hospital readmission.9–10 There is little information available regarding sex differences among hospitalized patients with diabetes or as a contributor to risk of readmission.11–15

There is increasing attention to reducing overall healthcare costs in the USA by reducing the frequency of preventable hospital readmissions.16–17 Women with diabetes have higher population-adjusted rates for both hospitalization and readmission when compared with men or women without diabetes.18–19 In one study examining national trends in hospital admissions, there was a greater increase in hospitalizations among women compared with men with diabetes, which was more pronounced in women aged 20–39 years.18

The Nationwide Readmissions Database demonstrated that diabetes increased the risk of readmission following percutaneous coronary intervention (PCI) to a greater extent in women compared with men.20 Flink et al21 reported an 8.5-fold increased risk of 30-day hospital readmissions for cardiovascular events among women but not men with poor glycemic measures when stratifying for demographics, medical history, discharge diagnosis, medical therapy, and reason for hospitalization. One retrospective analysis of hospitalizations identified female sex but not diabetes as an independent predictor of 30-day readmission for heart failure and recurrent coronary events following hospitalization for acute coronary syndrome requiring PCI.22

The Readmission and Comprehension of Diabetes Education at Discharge study is a prospective, non-blinded, observational study that examined the factors associated with risk of hospital readmission among patients with diabetes as a secondary diagnosis.23 This analysis was conducted to examine sex differences in demographics, metabolic and glycemic measures, diabetes-related complications, discharge disposition, and frequency of emergency room (ER) visits and readmissions within 90 days following an index hospitalization.

METHODS
This was a prospective, non-blinded, observational cohort study conducted at a single academic medical center.

Patient recruitment
Non-pregnant, non-critically ill, hospitalized patients with a secondary diagnosis of diabetes aged 18–90 years were recruited for this study between July 2017 and December 2018. Patients admitted with a primary diagnosis of hypoglycemia, diabetic ketoacidosis, or hyperglycemic hyperosmolar syndrome were excluded as were patients treated with insulin pump therapy. Potential subjects were identified from the general medicine service, the inpatient endocrine and diabetes consult services, and from daily reports of patients experiencing blood glucose (BG) <70mg/dL and >300mg/dL. A member of the study team approached the patients meeting the inclusion criteria to discuss the study and obtain consent. All participants provided written informed consent prior to data collection or study procedures.

Data collection
The following demographic data were collected through patient interviews and chart review: age, sex, body mass index (BMI), blood pressure (BP), duration and type of diabetes, employment status, educational level, date of most recent prior hospitalization, hemoglobin A1c (HbA1c), reason for admission, history of microvascular (retinopathy, neuropathy, nephropathy) or macrovascular (coronary artery disease, cerebrovascular event, peripheral vascular disease) diabetic-related complications, laboratory data (estimated glomerular filtration rate (eGFR), serum sodium, albumin, hematocrit), length of stay (LOS), discharge disposition, and admission and discharge diabetes medications.

Up to 10 BG measures obtained during the 48-hour time period preceding hospital discharge were obtained. Glucose values were measured in 4-hour intervals using either the lowest or the highest values if there were multiple measures in any one 4-hour interval to avoid overcounting of high or low BG values. For the majority of participants, BG measures were obtained before meals and bedtime in patients who were eating or every 6 hours in patients who were not eating.

Associations between nadir, peak, and mean BG values as well as glycemic variability measured as SD, coefficient of variability (CV), and BG range were investigated. A Diabetes Early Readmission Risk Indicator (DERRI) score was calculated for each patient and correlated with ER visits and hospital readmissions within 30 and 90 days following the index hospitalization.24

Study participants were contacted at 30 and 90 days following discharge to obtain information about ER visits and hospital readmissions. Information provided by the patients was validated by review of data available in the electronic health record (EHR). Information regarding ER visits and readmissions was obtained from the EHR for patients who could not be reached for a phone interview.

Statistical analysis
Descriptive statistics were reported using mean and SD or median with IQR for continuous variables, and frequencies with percentages for categorical variables. A t-test or a Mann-Whitney U test was performed to compare continuous variables and χ2 or Fisher’s exact test was used to compare categorical variables between men and women. Data were analyzed using SPSS V.24.0. Statistical significance was defined as p<0.05.

RESULTS
Study population
Of the 240 patients who consented to participate in this study, 20 were excluded. Reasons for exclusion included deterioration of clinical status during the
index hospitalization (n=10), use of an insulin pump (n=1), withdrawal of consent (n=5), or death prior to discharge (n=4) (figure 1). The 220 remaining participants included 120 men and 100 women, the majority of whom had type 2 diabetes (table 1).

Table 1 shows the clinical characteristics of study participants. There were no significant differences observed for age, race, BMI, BP, Hba1c, duration of diabetes, educational or employment status, glycemic measures preceding hospital discharge, hematocrit, LOS, DERRI scores, or hospital LOS between men and women. Serum creatinine was lower in women but there was no difference in eGFR. The percentage of men and women with microvascular, neuropathic, and macrovascular complications was also similar. The women in this study were less likely to be discharged to home with or without home...
**Table 1** Clinical characteristics of study participants by sex*

|                          | Men (n=120) | Women (n=100) | P value |
|--------------------------|-------------|---------------|---------|
| **Age (years)**          | 61.1±11.8   | 58.3±11.7     | 0.77    |
| **Race, white, n (%)**   | 92 (76.7)   | 74 (74.0)     | 0.647   |
| **BMI (kg/m²)**          | 32±8        | 32.3±10       | 0.791   |
| **Systolic BP (mm Hg)**  | 132.8±25.3  | 127±22.3      | 0.076   |
| **Diastolic BP (mm Hg)** | 74.9±12.6   | 73.9±13.7     | 0.572   |
| **Education, above high school, n (%)** | 52 (43.3) | 47 (47) | 0.586 |
| **Employment, n (%)**    |             |               | 0.134   |
| Unemployed               | 41 (34.2)   | 25 (25)       |         |
| Employed                 | 22 (18.3)   | 23 (23)       |         |
| Retired                  | 35 (29.2)   | 23 (23)       |         |
| Disabled                 | 22 (18.3)   | 29 (29)       |         |
| **Diabetes type 1/2/other, n (%)** | 9 (7)/104 (87)/7 (6) | 8 (8)/80 (80)/12 (12) | 0.353 |
| **HbA1c (%)**            | 8.2±2       | 8.4±2.28      | 0.473   |
| **Diabetes duration (years)** | 15.9±10.4 | 14.1±11.3 | 0.237 |
| **Number of diabetes complications** | 2.4±1.5 | 2.3±1.9 | 0.736 |
| **Length of stay (days), median (IQR)** | 6.0 (3.5–9.2) | 6.8 (4.1–11.2) | 0.152 |
| **Complications, n (%)** |             |               |         |
| Retinopathy              | 41 (25)     | 19 (19)       | 0.287   |
| Nephropathy              | 45 (38)     | 28 (28)       | 0.106   |
| Neuropathy               | 71 (59)     | 63 (63)       | 0.562   |
| CAD                      | 61 (51)     | 39 (39)       | 0.079   |
| CHF                      | 43 (36)     | 37 (37)       | 0.858   |
| CVA                      | 19 (16)     | 20 (20)       | 0.420   |
| PVD                      | 23 (19)     | 21 (21)       | 0.735   |
| **Reason for admission, n (%)** |         |               | 0.442   |
| Cardiac                  | 43 (35)     | 26 (26)       |         |
| Pulmonary                | 4 (3)       | 5 (5)         |         |
| Infection                | 17 (14)     | 21 (21)       |         |
| Trauma/injury            | 4 (3)       | 5 (5)         |         |
| Transplant               | 8 (7)       | 4 (4)         |         |
| Other                    | 44 (37)     | 39 (39)       |         |
| **Laboratory measures, median (IQR)** |         |               |         |
| Creatinine, mg/dL        | 1.3 (1.0–2.0) | 1.0 (0.7–1.5) | <0.001 |
| eGFR, mL/min/m²          | 58.5 (34–60) | 60.0 (40–60)  | 0.186   |
| Sodium, mmol/L           | 136 (134–139) | 138 (135–139) | 0.142   |
| Albumin, g/L             | 3.5 (3.0–3.8) | 3.6 (3.0–3.9) | 0.687   |
| Hematocrit (%)           | 34.3 (29.5–38.3) | 34.0 (30.7–38.2) | 0.975 |
| **Disposition, n (%)**   |             |               | 0.007   |
| Home                     | 118 (98)    | 90 (90)       |         |
| Discharge to SNF         | 2 (1.6)     | 10 (10)       |         |
| DERRI score              | 24.2±12.6   | 21.8±10.9     | 0.221   |

*Results are mean±SD unless otherwise indicated.
BMI, body mass index; BP, blood pressure; CAD, Coronary artery disease; CHF, Congestive heart failure; CVA, Cerebrovascular accident; DERRI, Diabetes Early Readmission Risk Indicator; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; PVD, Peripheral vascular disease; SNF, skilled nursing facility.
services and more likely to be discharged to a skilled nursing facility following the index hospitalization (1.6% vs 10%, p=0.007).

The most common reasons for admission included cardiovascular diagnoses (heart failure, myocardial infarction, heart rhythm abnormalities) and infection. Of the three most common reasons for admission, heart failure was listed as the primary reason for admission in 18.3% of men and 11% of women and myocardial infarction in 14.2% of men and 12% of women. Infection was the primary reason for admission in 12.5% of men and 18% of women.

The percentages of participants using insulin alone, insulin in combination with non-insulin therapies, or only non-insulin medications were similar between men and women prior to admission, during the index hospitalization, and at discharge (table 2). The majority of patients received insulin therapy alone (66% and 57%) or in combination with non-insulin therapy (19% vs 22%, p=0.444) during the index hospitalization. Changes in diabetes medications between admission and discharge occurred in 59% of men and 49% of women (p=0.132). Adjustment of insulin regimen (either insulin dose or type) was the most common change on discharge, occurring in 35% of men and 28% of women.

Nadir, peak, mean BG, and measures of glycemic variability (CV, SD, and BG range) during the 48-hour time period preceding hospital discharge were similar among men and women (table 3). Hypoglycemic but not hyperglycemic events in the 48-hour time period preceding hospital discharge occurred more frequently in men than in women. Among those experiencing hypoglycemia, three men and one woman experienced two BG values <70 mg/dL. Six men and three women had clinically significant hypoglycemia with BG values <54 mg/dL. Subgroup analysis of patients who did or did not experience hypoglycemia found no sex differences in readmissions or ER visits at 30 (p=1.0) or 90 (p=0.403) days.

Prior to the index hospitalization, 52% and 64% of men and 46% and 56% of women reported being hospitalized within the prior 90 days and 1 year, respectively (p=NS). Following the index hospitalization, men and women experienced a similar number of ER visits and hospital readmissions within the next 30 and 90 days of discharge (figure 2). The majority of participants in this study were white. Subgroup analysis by race and sex for readmissions or ER visits found no differences at 30 (p=0.384) or 90 (p=0.516) days. The absolute number of hospital readmissions per patient at 30 days (0.41±0.57 vs 0.34±0.57, p=0.144) and 90 days (0.82±1.04 vs 0.76±1.20, p=0.258) was also similar.

### DISCUSSION

This study demonstrates that men and women hospitalized with a secondary diagnosis of diabetes have similar diabetes duration, prevalence of diabetes-related complications, and glycemic measures as measured by HbA1c. There were no sex differences in the percentage of participants receiving insulin therapy alone or in combination with non-insulin therapies before, during, or following the index hospitalization. More women were discharged to a skilled nursing facility following the index hospitalization compared with men. This suggests the possibility of higher level of disability and/or less home support. Although there were no significant differences in employment status between men and women, a higher percentage of women were identified as disabled (table 1). The presence of adequate social support has been identified as an important component for facilitating the discharge process and preventing hospital readmission in patients with diabetes and other disorders.25 26

Cardiovascular disorders including heart failure, myocardial infarction, heart rhythm abnormalities, and infection were the most common reasons for admission among both men and women. Individuals with diabetes are at increased risk of CVD; however, this increase in

---

**Table 2** Diabetes medications at admission and hospital discharge

|               | Men n (%) | Women n (%) | P value |
|---------------|-----------|-------------|---------|
| Diabetes medications at admission |           |             |         |
| Insulin only  | 64 (53)   | 54 (54)     | 0.658   |
| Insulin+non-insulin agents | 28 (23)   | 19 (19)     |         |
| Non-insulin agents only | 25 (21)   | 26 (26)     |         |
| None          | 4 (3)     | 1 (1)       |         |
| Diabetes medications at discharge |           |             |         |
| Insulin only  | 79 (66)   | 57 (57)     | 0.444   |
| Insulin+non-insulin agents | 23 (19)   | 22 (22)     |         |
| Non-insulin agents only | 17 (14)   | 18 (18)     |         |
| None          | 1 (1)     | 3 (3)       |         |
| Patients (%) with change in diabetes medications between admission and discharge | 71 (59) | 49 (49) | 0.132 |

**Table 3** Glycemic outcome measures 48 hours preceding hospital discharge

|               | Men | Women | P value |
|---------------|-----|-------|---------|
| Nadir BG, mg/dL | 117.8±47.6 | 120.7±41.6 | 0.525   |
| Peak BG, mg/dL  | 294.8±81.6 | 299.3±110.7 | 0.846   |
| Mean BG, mg/dL  | 196.5±51.4 | 197.1±52.6 | 0.977   |
| SD, mg/dL      | 57.8±25.9 | 59.1±34.5 | 0.914   |
| BG range, mg/dL| 177.0±77.5 | 178.6±108.7 | 0.676   |

Percentage of participants with BG ≥1 mg/dL and <70 mg/dL

Data presented as mean±SD.

BG, blood glucose.
risk is greater in women when compared with the sex-matched population without diabetes.27–30 The absence of sex differences in the prevalence of diabetes-related macrovascular complications in this study is of interest, as these findings are consistent with prior publications demonstrating loss of the usual protective effect of female sex on risk of CVD observed in women without diabetes.5 28 29 31

Women are reported as being less likely to use or receive preventive medical care, which can be crucial in identifying and treating both microvascular and macrovascular complications.5 6 32 33 In one report, women diagnosed with diabetes in young adulthood were less likely to have access to annual eye and foot examinations.32 These disparities are more pronounced among women from lower socioeconomic backgrounds, where delays in diagnosis and treatment can increase disease-specific morbidity and mortality.6 28 29 32

Patients with diabetes often experience hypoglycemia or hyperglycemia during periods of hospitalization, both of which are reported as being associated with risk of readmission.9 34 35 With the exception of more hypoglycemic events in men, glycemic measures were otherwise similar in the 48 hours preceding hospital discharge in this study. Hypoglycemia is a common complication of inpatient insulin therapy and can result in increased morbidity and mortality that extend beyond the hospitalization when these events occur.36 37 The reasons for the more frequent hypoglycemia in men versus women were not investigated; however, over 90% of men and women in this report received insulin therapy, as recommended by current guidelines for inpatient glycemic management.38 39 Among the small percentage of patients receiving non-insulin therapy during hospitalization, none of the men and only one woman experiencing hypoglycemia received an insulin secretagogue, another risk factor for inpatient hypoglycemia.40 The findings of sex differences in hypoglycemic events are consistent with an earlier prospective cohort study of 250 patients which found that male sex was an independent predictor of asymptomatic hypoglycemia in hospitalized patients with diabetes.41 The reasons for this sex difference in hypoglycemic events are not known.

The frequency of ER visits and hospital readmissions at 30 and 90 days following the index hospitalization was similar among men and women in the current study. Prior studies that retrospectively examined risk factors for hospital readmission using large databases have variably demonstrated similar, less, or more frequent readmissions in women than in men.12 13 19 42 43 This variability is likely due in part to the type of database or study population examined. In one study of 737 hospitalized adults examining sex alone as a risk for readmission, men experienced more 30-day postdischarge ER visits and readmissions than women.42 However, the risk factors for these repeat visits differed between men and women. For men, social factors and depression were major predictors, while hospitalization in the preceding 6 months was the only identified factor for readmission among women.42 When examining the combination of sex and diabetes, there are less available data. In one study examining sex differences in healthcare expenditures, costs associated with ER visits and inpatient stays were equivalent between men and women.4

Changes in diabetes-related medications between time of admission and discharge are identified as a contributor to risk of hospital readmission in some but not all studies.44–46 In one study, women were more likely to have intensification of their diabetes regimen at the time of discharge.47 Another retrospective study of hospitalized patients with diabetes not on insulin prior to hospitalization showed no association with sex and medication

![Figure 2](http://drc.bmj.com/)  
**Figure 2** Emergency room (ER) visits and hospital (hosp) readmissions according to sex. d, days.
intensification at time of hospital discharge.44 In the current study, there were no sex differences in changes in diabetes medications between admission and discharge, with the most common medication change being an adjustment in dose or type of insulin.

There are several limitations to this observational study. One is that patients in this study were recruited from a single academic university hospital, limiting the ability to apply these findings to other hospitalized, non-critically ill patient populations with diabetes across the USA. Another is the small sample size when compared with studies conducted using large patient databases.12 18 19 45 This may have not allowed sufficient power to detect differences in outcomes that may in fact be present. An additional limitation is that information regarding social support at home that may have contributed to the higher percentage of women discharged to a skilled nursing facility was not obtained as part of this study. Finally, the population represented in this study was predominantly white. Although there were no race differences in readmission rates or ER visits, the percentage of non-white participants was small, which may have interfered with the ability to identify this as a potential contributor.

CONCLUSION

This study provides descriptive information regarding sex-based clinical and demographic characteristics among patients hospitalized with a secondary diagnosis of diabetes. Findings that were consistently observed between men and women included the presence of prediabetes and prediabetes poor glycemic measures as defined by mean HbA1c values >8%, as well as poor glycemic outcomes during hospitalization with mean BG levels >180 mg/dL associated with a high level of glycemic variability. The frequency of ER visits and hospital readmissions at 30 and 90 days was similar between men and women but exceeds what is reported in patient populations without diabetes.13 21 48 49 In summary, the risk of hospital readmission was high in both men and women in this study. The factors contributing to hospital readmissions may differ between the sexes. Further investigations into potentially remediable factors contributing to readmission risk are recommended.

Author affiliations

1Department of Medicine, UPMC, Pittsburgh, Pennsylvania, USA
2School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
3Division of Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
4Department of Medicine/Endocrinology, Temple University School of Medicine, Philadelphia, Pennsylvania, USA
5Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Contributors

NP was involved in the recruitment and follow-up of study participants, data collection and analysis, and abstract and manuscript preparation. NP was responsible for the draft of this manuscript. JS designed the study and data collection tools and study database, submitted the protocol to the institutional review board for approval, and worked with other members of the study team to engage them in subject recruitment and study methods. JS submitted abstracts to the American Diabetes Association and the Endocrine Society, where early findings of this study were presented. She participated in the preparation of this manuscript. DP was involved in the recruitment and follow-up of study participants, data collection and analysis, and abstract and manuscript preparation. EKF, DH, and KD were involved in the recruitment and follow-up of study participants and data collection, and reviewed and submitted comments on this manuscript. AD and LS were involved in study design and development of data collection tools and development of the study database, and reviewed and submitted comments on this manuscript. DJR provided consultation regarding the study design and use of the DERRI calculator that was used in the assessment of patient participants. He reviewed and submitted comments on this manuscript. UW met with investigators (JS, DP, MTK) to discuss statistical analyses and development of data collection tools over the course of this study and performed all statistical analyses. She reviewed and provided comments on the manuscript. MTK was the senior author and guarantor responsible for the overall content of this manuscript. MTK accepts full responsibility for the work and conduct of this study, had access to all study data, and controlled the decision to publish.

Funding

This work was supported in part by the National Institutes of Health through grant number UL1-TR-001857.

Competing interests

DJR receives research funding from AstraZeneca. The other authors have no multiplicity of interest to disclose.

Patient consent for publication

Not required.

Ethics approval

This study involves human participants and was approved by the University of Pittsburgh Institutional Review Board (reference number: PRO17050222). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

Data are available upon reasonable request. All data relevant to the study are included in the article.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Daniel J Rubin http://orcid.org/0000-0002-6871-6246
Mary T Korytkowski http://orcid.org/0000-0001-7131-8903

REFERENCES

1. Center for Disease Control. National diabetes statistics report 2020: estimates of diabetes and its burden in the United States 2020.
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 2018;41:917–28.
3. Leung M-YM, Pollack LM, Colditz GA, et al. Life years lost and lifetime health care expenditures associated with diabetes in the U.S., National health interview survey, 1997-2006. Diabetes Care 2015;38:460–8.
4. Williams JS, Bishu K, Dismuke CE, et al. Sex differences in healthcare expenditures among adults with diabetes: evidence from the medical expenditure panel survey, 2002-2011. BMC Health Serv Res 2017;17:259.
5. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 2016;37:278–316.
6. Marshall CJ, Rodriguez HP, Dyer W, et al. Racial and ethnic disparities in diabetes care quality among women of reproductive age in an integrated delivery system. Women's Health Issues 2020:30:191–9.
7. Bo S, Ciccone G, Grassi G, et al. Patients with type 2 diabetes had higher rates of hospitalization than the general population. J Clin Epidemiol 2004;57:1196–201.
8. De Berardis G, D’Ettorre A, Graziano G, et al. The burden of hospitalization related to diabetes mellitus: a population-based study. Nutr Metab Cardiovasc Dis 2012;22:605–12.
9. Cook CB, Kongable GL, Potter DJ, et al. Inpatient glucose control: a glycemic survey of 126 U.S. hospitals. J Hosp Med 2009;4:E7–14.
Rubin DJ, Recco D, Turchin A, et al. External validation of the diabetes early re-admission risk indicator (DERRI). *Endocr Pract* 2018;24:527–41.

Healy SJ, Black D, Harris C, et al. Inpatient diabetes education is associated with less frequent hospital readmission among patients with poor glycemic control. *Diabetes Care* 2013;36:2960–7.

Raval AD, Zhou S, Wei W, et al. 30-day readmission among elderly medicare beneficiaries with type 2 diabetes. *Popul Health Manag* 2015;18:256–64.

Cohn BA, Cirillo PM, Wingard DL, et al. Gender differences in hospitalizations for IDDM among adolescents in California, 1991. Implications for prevention. *Diabetes Care* 1997;20:1677–82.

Kirkhiaova D, Swan IJ, Rubin DJ, et al. Preventing hospital discharge risk factors for hospital readmission among patients with diabetes. *Med Care* 2018;56:634–42.

Zuckerman RB, Sheingold SH, Epstein AM. The hospital readmissions reduction program. *N Engl J Med* 2016;375:494.

Lee JM, Davis MM, Gebremariam A, et al. Age and sex differences in hospitalizations associated with diabetes. *J Womens Health* 2010;19:2033–42.

Gupta N, Crouse DL, Balram A. Individual and community-level income and the risk of diabetes rehospitalization among women and men: a Canadian population-based cohort study. *BMC Public Health* 2020;20:60.

Kwok CS, Potts J, Gouayoub B, et al. The effect of gender on unplanned readmissions after percutaneous coronary intervention (from the nationwide readmissions database). *Am J Cardiol* 2018;121:810–7.

Flink L, Mochani-Greenberger H, Mosca L. Gender differences in clinical outcomes among diabetic patients hospitalized for cardiovascular disease. *Am Heart J* 2013;165:972–8.

Lam M, Ahn HJ, Okajima K, et al. Gender differences in the rate of 30-day readmissions after percutaneous coronary intervention for acute coronary syndrome. *Womens Health Issues* 2019;29:17–22.

Pinskhaikova D, Swan IJ, Rubin DJ, et al. Patient understanding of discharge instructions for home diabetes self-management and risk for hospital readmission and emergency department visits. *Endocr Pract* 2021;27:561–6.

Rubin DJ, Harnsford EA, Golden SH, et al. Development and validation of a novel tool to predict hospital readmission risk among patients with diabetes. *Endocr Pract* 2016;22:1204–15.

Pollack AH, Backonja U, Miller AD, et al. Closing the gap: supporting patients’ transition to self-management after hospital discharge. *Proc SICGHI Conf Hum Factor Comput Syst* 2016:2016:3524–36.

Rubin DJ, Donnell-Jackson K, Jhingan R, et al. Early readmission among patients with diabetes: a qualitative assessment of contributing factors. *J Diabetes Complications* 2014;28:869–73.

Ametx C, Ekberg NR, Alvarsson M. Sex differences in type 2 diabetes: focus on disease course and outcomes. *Diabetes Metab Syndr Obes* 2014;7:409–20.

Booth GL, Kapral MK, Fung K, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. *Lancet* 2006;368:29–36.

Recarti C, Sep SJS, Stehouwer CDA, et al. Excess cardiovascular risk in diabetic women: a case for intensive treatment. *Curr Hypertens Rep* 2015;17:554.

Huxley RR, Peters AE, Mishra GD, et al. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 2015;3:198–206.